NIH R01 Grants: Recently Funded Projects and Award Sizes

New awards: 5,000; in the last 12 months
Median award: $682K; first-year award (total costs)
Middle half: $589K to $784K; 25th to 75th percentile
Top institute: NCI; 742 awards

About the NIH R01

The R01 funds a discrete, specified research project in the investigator's area of interest. It is the most common NIH grant and the usual benchmark for an independent research career.

Most R01s are submitted through parent announcements on the standard due dates, but many institutes also issue R01 notices for specific topics. Reviewers judge the importance of the research, its rigor and feasibility, and the expertise and resources behind it.

Project length: Usually up to 5 years
Budget: No set cap; requests of $500,000 or more in direct costs in any year need institute approval before you apply
Research Strategy: Usually 12 pages, plus a 1-page Specific Aims
Who applies: Investigators at eligible institutions; early-stage investigators get special consideration

Limits change between notices: the notice you apply to is what counts.

Open NIH R01 opportunities

All NIH funding

Recently funded NIH R01 projects

Quantifying Pollen Allergens with DNA Metabarcoding
Amy D Willis · University of Washington, WA · NIAID · $379K · Sep 30, 2026
Pollen allergy incurs a substantial burden of disease in the US, resulting in millions of lost work and school days and a negative economic impact of billions of dollars. Despite this burden, pollen monitoring has scarcely changed since the 1950s, consisting of volunteer-run monitoring stations in which pollen is…
Sequencing-free whole genome spatial transcriptomics at molecular resolution in aging tissue
Siyuan Wang · Yale University, CT · NIA · $781K · Sep 29, 2026
Recent breakthroughs in spatial transcriptomics technologies from us and others have enhanced our understanding of diverse cellular identities, compositions, interactions, spatial organizations, and functions. Yet existing spatial transcriptomics tools are still limited in either transcriptomic coverage or spatial…
Temporal Associations of Neuroinflammation with Alzheimer’s Disease Biomarkers and Cognition
Petrice M. Cogswell · Mayo Clinic Rochester, MN · NIA · $678K · Sep 29, 2026
Alzheimer's disease (AD) is characterized by the deposition of β-amyloid in the brain, followed by tau accumulation, neurodegeneration, and cognitive decline. β-amyloid has been a primary target for AD therapies and studies to date have shown a modest slowing of cognitive decline. Targeting additional processes…
Developing Integration and Modeling Frameworks for Single-Cell and Bulk Transcriptomics to Analyze Atlas-Scale Cell-Resolved Immune Variation Across Infections and Vaccinations
Leying Guan · Yale University, CT · NIAID · $570K · Sep 29, 2026
This project establishes a new computational paradigm to translate large-scale immune transcriptomic re- sources into robust, cell-resolved biological insights across infections, vaccines, and clinical contexts. Com- munity consortia have now generated transcriptomic resources of unprecedented scale such as the HIPC…
Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022)
Sagar Nigwekar · Massachusetts General Hospital, MA · FDA · $2.5M · Sep 29, 2026
Calciphylaxis is a rare but serious disorder of vascular calcification, characterized by occlusion of microvessels in the subcutaneous adipose tissue and dermis, leading to painful ischemic skin lesions. Calciphylaxis predominantly affects dialysis-dependent patients and is associated with high morbidity and…
Statistical Approaches for Data Harmonization for PET Imaging Studies of Alzheimer's Disease
Dana L Tudorascu · University of Pittsburgh at Pittsburgh, PA · NIA · $1.4M · Sep 29, 2026
PROJECT ABSTRACT This project focuses on the development of statistical methods for data harmonization of amyloid and tau PET neuroimaging studies of Alzheimer’s disease. Specifically, we will focus on developing methods for amyloid and tau PET harmonization for multiple sites and multiple tracers, for cross-sectional…
Stem- and Paneth cell-specific CD74 functions control gut immune responses
Nan Gao · Rutgers Biomedical and Health Sciences, NJ · NIDDK · $780K · Sep 29, 2026
CD74 is a type II transmembrane protein that binds Major Histocompatibility Complex class II (MHCII) and is required for antigen presentation by professional antigen presenting cells (APCs). Cell-surface CD74 also serves as a receptor for extracellular cytokines such as the macrophage migration inhibitory factor…
A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland Cancer
Alan L. Ho · Sloan-Kettering Inst Can Research, NY · FDA · $2.6M · Sep 28, 2026
Salivary gland cancers (SGCs) are rare tumors that constitute ~5% of all head and neck malignancies. They include >20 histologies, each with distinct biologic and clinical characteristics. Recurrent and/or metastatic (R/M) SGCs are incurable, and effective treatments are lacking. Molecular profiling studies have…
Macrophage interactions underlying adult testicular function
Tony J. Defalco · Cincinnati Childrens Hosp Med Ctr, OH · NICHD · $705K · Sep 28, 2026
Male hypogonadism, characterized by low testosterone, profoundly impacts the health and fertility of more than 10 million men in the US. Treatment options are limited and imperfect, and development of new therapeutic strategies is hindered by major gaps in our understanding of the cellular and molecular drivers of…
Central mechanisms of nausea and their modulation via non-invasive neurostimulation
Roberta Sclocco · Spaulding Rehabilitation Hospital, MA · NCCIH · $553K · Sep 24, 2026
Nausea is a highly aversive sensation that commonly accompanies chronic disorders and substantially reduces quality of life. Unlike vomiting, nausea arises from distinct neurocircuitry centered in the brainstem, particularly the nucleus tractus solitarii (NTS), which integrates vagal afferent input from visceral…
Patient-Derived Models to Identify Effective Therapies in Aggressive Large B-Cell Lymphomas
Abner Louissaint · Massachusetts General Hospital, MA · NCI · $600K · Sep 24, 2026
Large B-cell lymphomas (LBCLs) are the most common and aggressive lymphomas. Almost half of patients fail both chemotherapy and second-line immunotherapy, resulting in a critical need for models that can accurately replicate tumor biology and therapeutic responses. The long-term goal of this project is to create and…
Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients
Juan Fernando Vera · Marker Therapeutics, Inc., TX · FDA · $645K · Sep 24, 2026
Pancreatic cancer (PC) is an orphan disease affecting approximately 67,440 people annually in the US. With a 5-year relative survival of only 13% for all stages combined and 3.2% for metastatic disease, PC represents one of the most aggressive malignancies. Although surgical resection provides the best curative…
A retrospective and prospective study of leiomyosarcoma systemic therapy outcomes informed by tumor genomics
Robert G Maki · Sloan-Kettering Inst Can Research, NY · FDA · $345K · Sep 23, 2026
The treatment of cancer is changing with the increasingly detailed understanding of cancer genomics. For patients with sarcoma, our understanding lags behind more common cancers, both from the rarity (< 1 % of all cancers in humans) and heterogeneity of sarcomas. This heterogeneity is manifested by 70 or so histologic…
Prospective natural history study of extracellular vesicle metabolimic biomarkers of myotonic dystrophy
Thurman M Wheeler · Massachusetts General Hospital, MA · FDA · $400K · Sep 23, 2026
Myotonic dystrophy type 1 (dystrophia myotonica; DM1) is an inherited disorder that causes progressive muscle weakness and wasting. No effective treatments are available to slow or reverse symptoms. Candidate therapeutic antisense oligonucleotides (ASOs) are being tested in ongoing clinical trials. Monitoring drug…
Intraperitoneal CAR T-cell therapy for peritoneal mesothelioma
Prasad S. Adusumilli · Sloan-Kettering Inst Can Research, NY · FDA · $650K · Sep 23, 2026
Malignant peritoneal mesothelioma (MPeM) is a rare (annual incidence of <500 patients in the U.S.) and aggressive cancer of the abdominal serosa; systemic therapy alone achieves 5-year survival of only 9%. Regional therapies such as cytoreductive surgery (CRS) improve survival; however, 40% of patients present with…

Institutions with the most new NIH R01 awards

1University of Pennsylvania, PA122
2University of Michigan at Ann Arbor, MI121
3Johns Hopkins University, MD113
4University of Pittsburgh at Pittsburgh, PA110
5University of California, San Francisco, CA109
6Massachusetts General Hospital, MA106
7Washington University, MO102
8Yale University, CT101
9Stanford University, CA93
10Duke University, NC81

How to write it

All guides

Writing an NIH R01 application?

Grantee reads the notice, sets up every required section with its page limit and drafts each one with you, then checks the draft against the requirements before you submit.

Start free

Get new funding every Monday

New federal opportunities and upcoming deadlines for NIH R01 and more, in one short email. Free, unsubscribe anytime.

New NIH R01 awards with notice dates from Oct 27, 2025 to Oct 27, 2026, from NIH RePORTER. Amounts are the first-year award, direct plus indirect costs. Updated Oct 27, 2026.